Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9481150rdf:typepubmed:Citationlld:pubmed
pubmed-article:9481150lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C0034394lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C0524910lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C0085155lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C1516048lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C1550208lld:lifeskim
pubmed-article:9481150lifeskim:mentionsumls-concept:C1546805lld:lifeskim
pubmed-article:9481150pubmed:issue1lld:pubmed
pubmed-article:9481150pubmed:dateCreated1998-3-19lld:pubmed
pubmed-article:9481150pubmed:abstractTextA 69-item questionnaire measuring generic functioning and well-being and disease-specific health outcomes was developed and tested using the pre-treatment data from patients with chronic hepatitis C (CHC) participating in two randomized trials of interferon alpha-2b (n = 157). The questionnaire included all eight scales from the SF-36 and measures of nine other generic and disease-specific health concepts. Psychometric tests confirmed the assumptions underlying the construction and scoring of all generic and disease-specific scales. Cross-sectional tests of 'known groups' validity showed that CHC patients scored worse on the generic scales than patients with other chronic conditions and worse than a healthy general population. The generic and disease-specific scale scores were lower in the presence of physical findings of CHC, as hypothesized, but only the physical functioning and bodily pain scales were linked to cirrhosis or extreme alanine aminotransferase (ALT) ratios. This instrument will be useful in studies of health outcome among patients with CHC, a condition whose health burden appears to have been underestimated in studies to date.lld:pubmed
pubmed-article:9481150pubmed:languageenglld:pubmed
pubmed-article:9481150pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9481150pubmed:citationSubsetIMlld:pubmed
pubmed-article:9481150pubmed:statusMEDLINElld:pubmed
pubmed-article:9481150pubmed:monthJanlld:pubmed
pubmed-article:9481150pubmed:issn0962-9343lld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:WareJ EJEJrlld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:GanderIIlld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:HsuM AMAlld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:BungayK MKMlld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:BaylissM SMSlld:pubmed
pubmed-article:9481150pubmed:authorpubmed-author:SuganoDDlld:pubmed
pubmed-article:9481150pubmed:issnTypePrintlld:pubmed
pubmed-article:9481150pubmed:volume7lld:pubmed
pubmed-article:9481150pubmed:ownerNLMlld:pubmed
pubmed-article:9481150pubmed:authorsCompleteYlld:pubmed
pubmed-article:9481150pubmed:pagination39-55lld:pubmed
pubmed-article:9481150pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:meshHeadingpubmed-meshheading:9481150-...lld:pubmed
pubmed-article:9481150pubmed:year1998lld:pubmed
pubmed-article:9481150pubmed:articleTitleA questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C.lld:pubmed
pubmed-article:9481150pubmed:affiliationHealth Institute, New England Medical Center, Boston, MA 02111, USA. martha.bayliss@es.nemc.orglld:pubmed
pubmed-article:9481150pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9481150lld:pubmed